Overview of serotonin 1A receptor selective agents in anxiety disorders-the developmental situation in Japan

Summary

Serotonin 1A receptor selective agents have been developed throughout the world, but have different degrees of acceptance in different countries. Although buspirone has been marketed in the United States and Europe, positive results were not obtained for trials of buspirone in anxiety in Japan. Positive results were also not obtained for a related agent, ipsapirone, in Japan, although another related agent, tandospirone, has been demonstrated to show clinical efficacy in anxiety in Japanese studies. This may lead to the ultimate marketing of tandospirone for anxiety disorders in Japan.